Search clinical trials for: ER niacin (+) laropiprant (ERN/LRPT)

Total 744 results

Merck Sharp & Dohme LLC

Completed

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

MK0524B Bioequivalence Study (0524B-070)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

Diabetes Mellitus Type 2
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy/Tolerability Study (0524A-020)

Primary Hypercholesterolaemia | Mixed Hyperlipidaemia
Merck Sharp & Dohme LLC

Terminated

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Hypercholesterolemia, Familial | Heterozygous Familial Hypercholesterolemia
Organon and Co

Completed

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

MK0524A Bioequivalence Study (0524A-059)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)

Dyslipidemia
University of Oxford
Merck Sharp & Dohme LLC

Completed

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE)

Cardiovascular Disease | Diabetes Mellitus | Peripheral Arterial Disease | Coronary Heart Disease

United Kingdom
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy Study (0524B-022)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
University of Ioannina

Unknown

Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia

Dyslipidemia

Greece
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effects of Niacin Therapy on Lipoprotein Composition and Function

Cardiovascular Disease

United States
Abbott

Completed

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) (SUPREME)

Hyperlipidemia | Mixed Dyslipidemia

United States
Merck Sharp & Dohme LLC

Completed

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Hyperlipidemia | Hypercholesteremia
Instituto Aragones de Ciencias de la Salud
Hospital Miguel Servet

Completed

Effect of Niacin in the Lipoprotein (a) Concentration

Hypercholesterolemia

Spain
Rambam Health Care Campus

Unknown

The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker

Hypercholesterolemia

Israel
Calmy Alexandra
University Hospital, Geneva; Swiss National Science Foundation; Swiss Heart Foundation and other collaborators

Terminated

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

Atherosclerosis | HIV

Switzerland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
University Medical Centre Ljubljana

Completed

Niacin/Laropiprant and Endothelial Function

Coronary Heart Disease

Slovenia
Rhode Island Hospital

Completed

Improving Emotion Regulation Skills Among Adolescents Attempting to Lose Weight

Overweight and Obesity

United States
Merck Sharp & Dohme LLC

Terminated

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Hypercholesterolemia | Mixed Dyslipidemia
Daniel A. Siniawski
Merck Sharp & Dohme LLC

Terminated

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Coronary Artery Disease | Dyslipidemias

Argentina
Columbia University
Biolase Inc

Active, not recruiting

Peri-implantitis Treatment: Clinical Results of Conventional Treatment vs. the Addition of Biolase

Peri-Implantitis

United States
HealthPartners Institute

Terminated

Outreach-ER: A Dementia Care Intervention Program

Dementia

United States
Merck Sharp & Dohme LLC

Withdrawn

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) (ACHIEVE)

Hypercholesterolemia, Familial
Institut Investigacio Sanitaria Pere Virgili
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders

Completed

Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment (LOWHDL)

Type 2 Diabetes Mellitus | Dyslipidemia

Spain
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Uppsala University

Recruiting

Emotion Regulation Training for Adolescents With ADHD

ADHD | Emotion Regulation | Attention Deficit Disorder With Hyperactivity

Sweden
Jewish General Hospital

Recruiting

Emergency Room Visits and Older Patients (ER2) (ER2)

Emergencies | Length of Stay

Canada
Medical University of South Carolina
Georgia State University

Completed

PTSD Treatment and Emotion Regulation Skills Training for Veterans With Military Sexual Trauma (PE+ER) (PE+ER)

Anxiety Disorders | Stress Disorders, Post-Traumatic | Mental Disorder | Traumatic Stress Disorder

United States
Antengene Therapeutics Limited

Recruiting

A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma (TEACH)

Solid Tumor, Non-Hodgkin's Lymphoma

China, Taiwan
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Dyslipidemia
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI); Arizona Pharmaceuticals...

Completed

Effects of Niacin On Fatty Acid Trapping (NOFAT)

Dyslipidemia

United States
Ludwig-Maximilians - University of Munich

Terminated

Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Metabolic Syndrome | Hyperlipoproteinemia

Germany
Asieris Pharmaceuticals (AUS) Pty Ltd.

Completed

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Bladder Cancer

Australia
Member Companies of the Opioid PMR Consortium

Terminated

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Opioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic Abuse

United States
Washington State University
American Society for Pain Management Nursing

Recruiting

Empowered Relief Delivered by Nurses (ERA)

Pain, Chronic

United States
National Institute of Mental Health (NIMH)

Completed

Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People

Pharmacokinetics | Adult

United States
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Cholesterol Levels (0524A-048)

Hypercholesterolemia | Hyperlipidemia
Bayside Health
National Health and Medical Research Council, Australia

Terminated

Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease

Peripheral Arterial Disease

Australia
Korea University Anam Hospital

Completed

YSGG Application in Periodontal Treatment

Periodontal Diseases

Korea, Republic of
Lotus Pharmaceutical

Completed

Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine

Migraine Without Aura | Migraine With Aura

Taiwan
Kowa Research Institute, Inc.

Completed

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

Dyslipidemia

United States

3

Subscribe